Navigation Links
PTC Therapeutics Closes $30 Million Financing
Date:7/23/2012

SOUTH PLAINFIELD, N.J., July 23, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors. 

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

"This funding will support our continued late-stage clinical development of ataluren in nonsense mutation Duchenne and Becker muscular dystrophy and nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "This is our first equity financing round in over two years, and serves as an important validation of the ataluren program and our commitment for its further development." 

PTC recently announced results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis. An extension study for patients previously enrolled in the trial is ongoing. An open-label trial for Duchenne and Becker muscular dystrophy patients who received ataluren in a prior, PTC-sponsored clinical study is also ongoing while PTC continues the dialogue with regulatory authorities regarding next steps in ataluren's development. In both Duchenne and Becker muscular dystrophy and cystic fibrosis, ataluren has demonstrated clinically meaningful trends in the primary endpoints and in supporting secondary endpoints. It was generally well tolerated; serious adverse events were infrequent and not considered to be related to the drug. PTC owns the worldwide rights for ataluren across all indications.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
2. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
3. Echo Therapeutics Expands License Agreement with Ferndale Pharma
4. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
5. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
6. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
7. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
8. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
9. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
10. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
11. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ohio, July 30, 2015 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year. Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior-year period. Adjusted EPS was $2.80 , ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... Nov. 3, 2010 DURECT Corporation (Nasdaq: DRRX ... September 30, 2010. Total revenues were $8.1 million for the ... for the three months ended September 30, 2009; revenues in ... of certain excipients used in REMOXY® to King Pharmaceuticals in ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), a ... tumor specific data to enhance the value of oncology drugs, ... Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was enacted as ... 2010. About Champions Biotechnology, Inc. Champions Biotechnology, ...
Cached Medicine Technology:DURECT Corporation Announces Third Quarter 2010 Financial Results 2DURECT Corporation Announces Third Quarter 2010 Financial Results 3DURECT Corporation Announces Third Quarter 2010 Financial Results 4DURECT Corporation Announces Third Quarter 2010 Financial Results 5DURECT Corporation Announces Third Quarter 2010 Financial Results 6DURECT Corporation Announces Third Quarter 2010 Financial Results 7Champions Biotechnology Awarded $1.46 million in Grants 2
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for ... Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... for the annual Lollapalooza. This unique and unbelievably popular festival attracts the best ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride ... in Downtown Memphis on October 3, 2015. The Ride to Fight On is a ... research between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 ... Pasadena courthouse was contained and extinguished by the city’s fire department before it caused major ... at the time of the fire, and it was a fire alarm system that tipped ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and potential patients alike on various plastic surgery procedures including, but not limited ... such popular dermatology procedures like Botox and fillers. , Staying up to ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2
... Training physicians in mindfulness meditation and communication skills can ... and their patients, University of Rochester Medical Center researchers ... the journal Academic Medicine . As ways ... a sense of community among physicians and providing time ...
... , THURSDAY, April 26 (HealthDay News) -- The ... from 10 a.m. to 2 p.m., the U.S. Drug Enforcement ... safely dispose of unwanted and unused prescription drugs. At ... than 377,000 pounds (188.5 tons) of unwanted or expired medications ...
... Thompson HealthDay Reporter , WEDNESDAY, April 25 (HealthDay ... with groups as diverse as the American Cancer Society and ... fragrance as a therapy that can complement traditional health care. ... cure illness, but research has found it can help reduce ...
... HealthDay Reporter , WEDNESDAY, April 25 (HealthDay News) ... drugs, their stroke risk goes up quickly, new research ... they are taking warfarin or a newer, more expensive ... heart rhythm in which the upper chambers of the ...
... (April 25, 2012) John W. Tsuang, M.D., principal ... Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven ... Medicine, is spearheading a Phase I clinical safety trial ... Ibudilast when administered with metamphetamine (MA), an addictive stimulant ...
... Experts are proposing a new model of care ... present with various emergent cardiovascular conditions which require ... of mortality, in an article published April 24 ... as ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, ...
Cached Medicine News:Health News:Physician's mindfulness skills can improve care for patient and provider 2Health News:Aromatherapy: More Than Just a Pleasant Scent? 2Health News:Aromatherapy: More Than Just a Pleasant Scent? 3Health News:Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat 2Health News:LA BioMed's Dr. John Tsuang examines effects of Ibudilast and metamphetamines 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... of abuse tests are highly accurate in detecting ... cut-off as confirmed by GC/MS testing. This assay ... alternative method (such as GC/MS) must be used ... judgment should be applied to any drug of ...
AccuSign® DOA Series Opiates Test...
... The QuickScreen™ At Home Drug Test is ... the FDA for home use. The kit includes ... easy to read instructions, a handbook with frequently ... ship the sample to the laboratory if the ...
Medicine Products: